Lasa Supergenerics Ltd - LASA SUPERGENERI Share Price

Sector: Pharmaceuticals | ISIN: INE670X01014
₹ 23.25 (-1.90%) icon30 May, 2023, 3:29:54 PM
Open
₹ 24.20
Prev. Close
₹ 23.70
Turnover(lac)
₹ 6.99
Day's High
₹ 24.20
Day's Low
₹ 23.10
52 Wk High
₹ 46.50
52 Wk Low
₹ 17.10
Book Value
₹ 26.84
Face Value
₹ 10.00
Mkt. Cap (Cr.)
₹ 116.49
P/E
0.00
EPS
0.00
Div. Yield
0.86

Lasa Supergenerics Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/30/2023 3:29:54 PM

    ₹ 23.25 -0.45 -1.90
  • Open
  • ₹ 24.2
  • Prev. Close
  • ₹ 23.7
  • Turnover(Lac.)
  • ₹ 7
  • Day's High
  • ₹ 24.2
  • Day's Low
  • ₹ 23.1
  • 52 Week's High
  • ₹ 46.5
  • 52 Week's Low
  • ₹ 17.1
  • Book Value
  • ₹ 26.84
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 116.49
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0.86

Lasa Supergenerics Ltd Corporate Actions

22 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Mar , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

06 Feb , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

06 Feb , 2023

12:00 AM

08 Nov , 2022

12:00 AM

08 Nov , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

05 Sep , 2022

12:00 AM

AGM

Announcement date: 05 Sep , 2022

View Details

11 Apr , 2022

12:00 AM

Dividend

Dividend amount: 0.25
Announcement date: 11 Apr , 2022

View Details

05 Sep , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

02 Aug , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

02 Aug , 2022

12:00 AM

29 Aug , 2022

12:00 AM

BookCloser

View Details

Lasa Supergenerics Ltd SHAREHOLDING SNAPSHOT
30 May , 2023 | 05:29 PM

PROMOTER - TOTAL53.65%

Indian: 53.65%

Foreign: 0%

NON-PROMOTER - TOTAL 46.35%

Institutions: 0.00%

Non-Institutions: 46.35%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Lasa Supergenerics Ltd News and Update

Image not found
  • 1 day ago |
  • 5:39 PM

Recommendation: Add; Target Price: Rs 165

Image not found
  • IIFL News Service |
  • 23 May, 2023 |
  • 5:30 PM
Article Image
Image not found
  • IIFL News Service |
  • 22 May, 2023 |
  • 5:28 PM
ad IconAd Image

Lasa Supergenerics Ltd FINANCIALS

No Data Available To Display Chart

Lasa Supergenerics Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Lasa Supergenerics Ltd

  • Omkar P Herlekar
  • Chairman & Managing Director
  • Manali Bhagtani
  • Addtnl Independent Director
  • Shivanand Hedge
  • Whole-time Director
  • Hardesh Tolani
  • Independent Director
  • Ajay Sukhwani
  • Independent Director
  • Ekta Gurnasinghani
  • Independent Director
  • Mitti M Jain
  • Company Sec. & Compli. Officer

Summary

Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra. It specialises in catalyst chemistry and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain, the Company is fully backward integrated for its key molecules-from discovery research up to full-scale bulk production. The Companys marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future.The Company announced the launching of 2 new block buster products with all-time strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the... Read More


Reports by Lasa Supergenerics Ltd


Reports by Lasa Supergenerics Ltd